Neuproscan for Web

Product snapshot

Neuproscan is a diagnostic platform that applies advanced machine learning to brain MRI scans to spot early signs of dementia, including Alzheimer’s disease long before clinical symptoms appear. Designed for use alongside routine imaging, it highlights subtle structural and signal changes that can escape standard visual review, helping clinicians identify patients at elevated risk during the preclinical phase.

How it works

The system uses a deep-learning model trained on a large repository of MRI studies to recognize complex, high-dimensional patterns associated with neurodegeneration. By evaluating imaging data at a very fine scale — down to pixel-level features — Neuproscan extracts biomarkers that are difficult to quantify by eye. Its output is a probabilistic assessment of future cognitive decline that clinicians can incorporate into their diagnostic workflow.

Clinical value

Neuproscan functions as a decision-support tool that complements the clinician’s judgment. It provides a second, data-driven perspective on the likelihood of Alzheimer’s development, aiding in risk stratification, monitoring, and earlier initiation of therapeutic or lifestyle interventions. Because it relies exclusively on routinely collected MRI, it is non-invasive and can be integrated without additional procedures for the patient.

Primary benefits

• Enhances early identification of neurodegenerative changes before symptoms are obvious
• Supplies clinicians with a quantitative, image-based risk estimate to inform care decisions
• Operates using standard MRI scans, avoiding invasive tests or extra appointments
• Detects nuanced imaging signatures that may be missed during conventional reads

Intended outcome

By filling a diagnostic gap in the pre-symptomatic window, Neuproscan aims to improve timely intervention planning and ultimately support better long-term outcomes for patients and families facing dementia.